Mirvetuximab treatment cycle instructions

Mirvetuximab (Mirvetuximab) is an innovative drug that combines a folate receptor alpha (FRα) antibody and a microtubule inhibitor. It is mainly used to treat patients with epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer that is resistant to platinum drugs, especially those FRα-positive adult patients who have received 1 to 3 systemic treatments. As a targeted therapy, somituximab adopts a precise treatment strategy to improve efficacy and reduce damage to normal cells.

Somituximab is administered by intravenous infusion, usually every 3 weeks. The length of the treatment cycle varies depending on the patient's specific condition, but generally, patients continue treatment until disease progression or unacceptable toxicity. The periodicity and flexibility of this treatment modality allows somituximab to adjust treatment plans based on patient response, maximizing treatment effectiveness and reducing the impact of side effects on patients' daily lives.

In clinical application, somituximab is mainly targeted at FRα-positive patients. The tumor cells of these patients express more folate receptor α on the surface, and this receptor is the target of somituximab . By targeting folate receptor alpha, somituximab can effectively deliver therapeutic drugs directly to tumor cells, maximizing its anti-tumor effect while reducing its impact on normal cells. This mechanism makes somituximab a new treatment option for patients with platinum-resistant ovarian cancer.

In terms of treatment course setting, the dosing interval of somituximab is once every 3 weeks. Such a cycle not only helps patients tolerate it, but also ensures that the drug maintains an effective concentration in the body. Treatment usually continues until the disease shows progression or the patient experiences serious side effects. It should be noted that during the treatment process, patients need to undergo regular medical examinations to monitor the effects of the drug and possible adverse reactions.

Keyword tags: somituximab,Mirvetuximab, ELAHERE, folate receptor α, treatment cycle, platinum-resistant ovarian cancer, intravenous infusion, treatment interval

Reference materials:https://www.elahere.com/